Drug Costs Up in 2013/14 for Canadian Public Drug Plans Due to Increased Spending on High-Cost Drugs; Reduced Savings From Generics
Patented Medicine Prices Review Board releases second edition of flagship report on Canadian public drug plan expenditures
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 05/25/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the second edition of CompassRx, its flagship annual report that monitors major developments in drug pricing and reimbursement in Canada, analyzes trends, and measures their impact on expenditure levels. Building on the findings of the first edition, focuses on the 2013/14 fiscal year and provides a retrospective review of trends since 2009/10.
The report shows that spending by Canadian public drug plans increased by an average of 2.0% in 2013/14, reversing a multi-year trend of low or negative growth. This was due to a surge in the use of higher-cost drugs, such as biologics, and a substantial reduction in savings from the use of lower-priced generic versions of brand-name drugs. As anticipated in last year''s report, these findings suggest that the "patent cliff" era of recent years, which saw public drug plans benefit from many top-selling "blockbuster" brand-name drugs of the past decade reaching the end of their patent terms and facing generic competition for the first time, has run its course. Of the few remaining blockbuster drugs on the Canadian market, none lost patent protection in 2013/14.
In addition to increased spending on high-cost drugs, in recent years most public drug plans have been spending more on dispensing costs, which grew by 5.9% or $122.2 million in 2013/14 and accounted over time for a greater share (22.3%) of overall public drug plan spending on prescription drugs.
is available on the PMPRB website in PDF and accessible HTML formats.
Quick Facts
Related Products
Associated Links
Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board is a respected public agency that makes a unique and valued contribution to sustainable spending on pharmaceuticals in Canada by:
About the NPDUIS initiative
The National Prescription Drug Utilization Information System (NPDUIS) is a research initiative established by federal, provincial, and territorial Ministers of Health in September 2001. It is a partnership between the Patented Medicine Prices Review Board and the Canadian Institute for Health Information (CIHI).
The NPDUIS initiative provides policy makers and public drug plan managers with critical analyses of price, utilization and cost trends so that Canada''s health care system has more comprehensive and accurate information on how prescription drugs are being used and on sources of cost pressures.
The main data source for this report is the NPDUIS Database, developed by the CIHI.
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2016 - 12:30 Uhr
Sprache: Deutsch
News-ID 1437570
Anzahl Zeichen: 2406
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 395 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Drug Costs Up in 2013/14 for Canadian Public Drug Plans Due to Increased Spending on High-Cost Drugs; Reduced Savings From Generics
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
